Application of diphenyl pyrazole compound in preparation of medicine for treating tuberculosis
By developing diphenylpyrazole compounds as anti-tuberculosis drug sensitizers, the problem of anti-tuberculosis drug resistance in the prior art has been solved, the bactericidal activity against drug-resistant tuberculosis strains has been significantly improved, and a broad-spectrum treatment plan has been provided , solves the problems of lack of broad spectrum of sensitizers and high cost of developing new drugs in the prior art.
Patent Information
- Application Number
- CN202410283709.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-31
- Filing Date
- 2024-03-13
- Publication Date
- 2024-12-03
AI Technical Summary
Among the existing tuberculosis treatment plans, the drug resistance problem of anti-tuberculosis drugs has led to the prevalence of drug-resistant tuberculosis strains, lack of effective broad-spectrum anti-resistant tuberculosis treatment plans, the development of new drugs is high and the speed is slow, and there is a lack of existing sensitizers. Broad spectrum.
Developing a diphenylpyrazole compound as an antituberculosis drug sensitizer/efficacy agent can significantly enhance the bactericidal of non-drug-resistant and drug-resistant tuberculosis strains by drugs such as rifampin, ethambutol, isoniazid Activity, used to treat tuberculosis, including drug-resistant tuberculosis.
This diphenylpyrazole compound significantly improves the sensitivity and effectiveness of existing anti-tuberculosis drugs to drug-resistant tuberculosis strains, provides broad-spectrum synergistic activity, and can effectively treat non-drug-resistant and drug-resistant tuberculosis, especially resistant Drug tuberculosis.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of medicines, and in particular relates to use of diphenylpyrazole compounds in preparing medicines for treating tuberculosis. Background Art
[0002] Tuberculosis is a chronic infectious disease caused by mycobacteria. It is also the single infectious disease that causes the most deaths and is ranked as one of the top ten causes of death in the world. The global tuberculosis report released by the World Health Organization (WHO) shows that in recent years, there are about 10 million new cases of tuberculosis each year worldwide. The current standard regimen for tuberculosis treatment is the WHO-recommended strategy of combined treatment with isoniazid, rifampicin, ethambutol and pyrazinamide for 6 months. The long-term use of these first-line anti-tuberculosis drugs has led to an increase in the resistance rate of mycobacteria. The prevalence of drug-resistant tuberculosis strains has become a new global public health crisis, seriously threatening the development of the global anti-tuberculosis cause. The WHO survey report shows that 3.4% of new tuberculosis cases and 18% of previously treated tuberculosis cases worldwide are multidrug-resistant or rifampicin-resistant tuberculosis. The global market is in urgent need of effective anti-drug resistant tuberculosis treatment options.
[0003] There are two main research directions for the treatment of drug-resistant tuberculosis: one is to develop new anti-tuberculosis drugs to replace anti-tuberculosis drugs with severe drug resistance; the other is to develop anti-tuberculosis drug sensitizers to improve the efficacy of existing anti-tuberculosis drugs. The research and development of new anti-tuberculosis drugs is costly and has a long cycle. According to statistics, it takes about 10-15 years for candidate drugs to develop from the preclinical stage to the clinical stage, costing about US$1 billion, and the speed of new drug development is far slower than the speed of the development of drug-resistant tuberculosis strains. For more than half a century, the only three non-first-line anti-tuberculosis drugs approved for marketing worldwide are bedaquiline, delamanid and putomani, and there are no new first-line anti-tuberculosis drugs. In my country, only bedaquiline has been approved for marketing. Compared with the development of new anti-tuberculosis drugs, the development of sensitizers to improve the efficacy of existing anti-tuberculosis drugs is relatively low-cost, safe and efficient. There are two main types of antimicrobial sensitizers commonly used in clinical practice, namely sulfonamide sensitizers and β-lactamase inhibitors that were launched in the 1970s and 1980s. However, these two types of sensitizers lack broad-spectrum properties and have no significant sensitizing activity against existing anti-tuberculosis drugs such as rifampicin, ethambutol, isoniazid, and pyrazinamide. With the increase in the types of drug-resistant tuberculosis strains and the widespread prevalence of multidrug-resistant tuberculosis strains, it is imperative to develop new, broad-spectrum anti-tuberculosis drug sensitizers / enhancers. Summary of the invention
[0004] Anti-tuberculosis drug sensitizers / synergists are the most economical and effective solution to the current prevalence of drug-resistant tuberculosis strains. In view of the deficiencies of the prior art, the present invention provides a class of anti-tuberculosis drug sensitizers / synergists with novel structures, which can significantly enhance the bactericidal activity of anti-tuberculosis drugs with different structures and different action mechanisms, such as rifampicin, ethambutol, isoniazid, etc., against non-resistant tuberculosis strains and drug-resistant tuberculosis strains, and have broad-spectrum synergistic activity.
[0005] Therefore, the present invention proposes a class of diphenylpyrazole compounds, which show synergistic enhancing activity to different types of anti-tuberculosis drugs such as rifampicin, ethambutol, isoniazid, etc., and can be used as a broad-spectrum anti-tuberculosis drug sensitizer / enhancer for the treatment of tuberculosis (including non-drug-resistant tuberculosis and drug-resistant tuberculosis, especially drug-resistant tuberculosis).
[0006] The present invention provides use of the following diphenylpyrazole compounds of general formula (I) or pharmaceutically acceptable salts thereof in preparing drugs for treating tuberculosis (including non-drug-resistant tuberculosis and drug-resistant tuberculosis, especially drug-resistant tuberculosis).
[0007] Preferably, the diphenylpyrazole compound of general formula (I) or a pharmaceutically acceptable salt thereof is used in the preparation of an anti-tuberculosis drug sensitizer / synergist.
[0008] In the present application, the terms "sensitizer" and "synergist" have the same meaning and can be used interchangeably, and they can enhance the sensitivity and effectiveness of anti-tuberculosis drugs.
[0009] Preferably, the diphenylpyrazole compound of general formula (I) or a pharmaceutically acceptable salt thereof is used in the preparation of a drug for treating non-drug-resistant tuberculosis and drug-resistant tuberculosis.
[0010] Preferably, the anti-tuberculosis drug is a broad-spectrum anti-tuberculosis drug.
[0011] Preferably, the anti-tuberculosis drug is selected from one or more of isoniazid, rifampicin, ethambutol, pyrazinamide, bedaquiline, delamanid and putamanid.
[0012] More preferably, the anti-tuberculosis drug is selected from one or more of isoniazid, rifampicin and ethambutol.
[0013] In certain specific embodiments, the anti-tuberculosis drugs are: rifampicin and ethambutol.
[0014] In certain specific embodiments, the anti-tuberculosis drugs are: rifampicin and isoniazid.
[0015] In certain specific embodiments, the anti-tuberculosis drugs are: isoniazid and ethambutol.
[0016] In certain specific embodiments, the anti-tuberculosis drugs are: rifampicin, isoniazid and ethambutol.
[0017] Preferably, the drug comprises a diphenylpyrazole compound of general formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
[0018] Further preferably, the drug comprises a diphenylpyrazole compound of general formula (I) or a pharmaceutically acceptable salt thereof and an anti-tuberculosis drug, and a pharmaceutically acceptable excipient.
[0019] More preferably, the weight ratio of the anti-tuberculosis drug to the diphenylpyrazole compound of general formula (I) or its pharmaceutically acceptable salt is 0.05-200:0.5-100, preferably 0.1-100:1-50, more preferably 0.1-50:3-30, more preferably 0.1-30:5-20, more preferably 0.25-16:10.
[0020] In some embodiments, in the drug,
[0021] When the anti-tuberculosis drug is rifampicin and the diphenylpyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is compound PXG22, the weight ratio of rifampicin to compound PXG22 is 0.05-200:0.5-100, preferably 0.5-100:1-50, more preferably 1-30:2-30, more preferably 1-10:5-20, more preferably 4:10; or,
[0022] When the anti-tuberculosis drug is ethambutol, and the diphenylpyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is compound PXG22, the weight ratio of ethambutol to compound PXG22 is 0.1-50:0.5-100, preferably 0.2-30:1-50, more preferably 0.5-20:2-30, more preferably 0.8-10:5-20, more preferably 1:10; or,
[0023] When the anti-tuberculosis drug is isoniazid, the diphenylpyrazole compound of general formula (I) or a pharmaceutically acceptable salt thereof is compound PXG22, the weight ratio of ethambutol to compound PXG22 is 0.1-20:0.5-100, preferably 0.1-20:1-50, more preferably 0.1-10:2-30, more preferably 0.1-5:5-20, more preferably 0.25:10; or,
[0024] When the anti-tuberculosis drug is rifampicin and the diphenylpyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is compound PXG1, the weight ratio of rifampicin to compound PXG1 is 0.5-100:0.25-100, preferably 0.5-50:0.3-50, more preferably 0.5-20:0.5-20, more preferably 1-10:1-5, more preferably 4:2.5; or,
[0025] When the anti-tuberculosis drug is rifampicin, and the diphenylpyrazole compound of the general formula (I) or a pharmaceutically acceptable salt thereof is compound PXG2, the weight ratio of rifampicin to compound PXG2 is 0.5-100:0.25-100, preferably 0.5-50:0.3-50, more preferably 0.5-20:0.5-20, more preferably 1-10:1-5, more preferably 4:2.5; or,
[0026] When the anti-tuberculosis drugs are rifampicin and ethambutol, and the diphenylpyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is compound PXG22, the weight ratio of rifampicin, ethambutol and compound PXG22 is 0.05-200:0.1-50:0.5-100, preferably 0.5-100:0.2-30:1-50, more preferably 1-30:0.5-20:2-30, more preferably 1-10:0.8-10:5-20, more preferably 4:1:10; or,
[0027] When the anti-tuberculosis drugs are rifampicin and isoniazid, and the diphenylpyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is compound PXG22, the weight ratio of rifampicin, isoniazid and compound PXG22 is 0.05-200:0.1-20:0.5-100, preferably 0.5-100:0.1-20:1-50, more preferably 1-30:0.1-10:2-30, more preferably 1-10:0.1-5:5-20, more preferably 4:0.25:10; or,
[0028] When the anti-tuberculosis drugs are isoniazid and ethambutol, and the diphenylpyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is compound PXG22, the weight ratio of isoniazid, ethambutol and compound PXG22 is 0.1-50:0.1-50:0.5-100, preferably 0.2-30:0.2-30:1-50, more preferably 0.5-20:0.5-20:2-30, more preferably 0.8-10:0.8-10:5-20, more preferably 1:1:10; or,
[0029] When the anti-tuberculosis drugs are rifampicin and ethambutol, and the diphenylpyrazole compound of the general formula (I) or a pharmaceutically acceptable salt thereof is compound PXG1, the weight ratio of rifampicin, ethambutol and compound PXG1 is 0.5-100:0.1-50:0.25-100, preferably 0.5-50:0.2-30:0.3-50, more preferably 0.5-20:0.5-20:0.5-20, more preferably 1-10:0.8-10:1-5, more preferably 4:1:2.5; or,
[0030] When the anti-tuberculosis drugs are rifampicin and isoniazid, and the diphenylpyrazole compound of the general formula (I) or a pharmaceutically acceptable salt thereof is compound PXG1, the weight ratio of rifampicin, isoniazid and compound PXG1 is 0.5-100:0.1-20:0.25-100, preferably 0.5-50:0.1-20:0.3-50, more preferably 0.5-20:0.1-10:0.5-20, more preferably 1-10:0.1-5:1-5, more preferably 4:0.25:2.5; or,
[0031] When the anti-tuberculosis drugs are isoniazid and ethambutol, and the diphenylpyrazole compound of general formula (I) or its pharmaceutically acceptable salt is compound PXG1, the weight ratio of isoniazid, ethambutol and compound PXG1 is 0.1-20:0.1-50:0.5-100, preferably 0.1-20:0.2-30:0.5-50, more preferably 0.1-10:0.5-20:0.5-20, more preferably 0.1-5:0.8-10:1-10, more preferably 0.25:1:5.
[0032] Preferably, the tuberculosis strain is a non-drug-resistant strain of Mycobacterium tuberculosis H37rv or a drug-resistant strain of Mycobacterium tuberculosis IMCASHD1.
[0033] In addition, the present invention provides a drug for treating tuberculosis, which comprises a diphenylpyrazole compound of general formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
[0034] Preferably, the present invention provides a drug for treating tuberculosis, comprising a diphenylpyrazole compound of general formula (I) or a pharmaceutically acceptable salt thereof and an anti-tuberculosis drug, and a pharmaceutically acceptable excipient.
[0035] Preferably, the anti-tuberculosis drug is selected from one or more of isoniazid, rifampicin, ethambutol, pyrazinamide, bedaquiline, delamanid and putamanid.
[0036] More preferably, the anti-tuberculosis drug is selected from one or more of isoniazid, rifampicin and ethambutol.
[0037] Preferably, the tuberculosis includes non-drug-resistant tuberculosis and drug-resistant tuberculosis, especially drug-resistant tuberculosis.
[0038] In addition, the present invention provides a method for treating tuberculosis, comprising administering the above-mentioned drug for treating tuberculosis to a patient.
[0039] The diphenylpyrazole compound of general formula (I) or a pharmaceutically acceptable salt thereof is:
[0040]
[0041] in:
[0042] R 1 Can be:
[0043] (1) amide group -NH-CH(O) which is unsubstituted or substituted with one or more of the following substituents;
[0044] (a)-C 1~6 Alkyl-R 3 , -C 3~8 Cycloalkyl-R 3 , -C 2~6 Alkenyl-R 3 , -C 2~6 Alkynyl-R 3 、-NH-R 3 、-N(R 3 ) 2 、-C(O)-R 3 、-NH-C 1~6 Alkyl-R 3 , -C 1~6 Alkyl-NH-R 3 , -C 1~6 Alkyl-N(R 3 ) 2 , -C 1~6 Alkyl-OR 3 , -C 3~8 Cycloalkyl-OR 3 、-OC 1~6 Alkyl-R 3 , -C 1~6 Alkyl-OC 1~6 Alkyl-R 3 、-C(O)-NH-R 3 、-C(O)-N(R 3 ) 2 、-NH-C(O)-R 3 , -C 1~6 Alkyl-NH-C(O)-R 3 , -C 1~6 Alkyl-NH-C(O)-OR3 、-NH-C(O)-C 1~6 Alkyl-R 3 、-NH-C(O)-C 1~6 Alkyl-OR 3 、-C(O)-NH-C 1~6 Alkyl-R 3 or -C 1~6 Alkyl-SR 3 ;
[0045] The R 3 Each is independently selected from: H, O, S, =NH, amino, halogen, cyano, -C 1~6 Alkyl, -C 3~8 Cycloalkyl, -SC 1~6 Alkyl, -S-OH, -SO 2 -C 1~6 alkyl, -6 to 14-membered aryl, -5 to 14-membered heterocyclic group, -5 to 14-membered heteroaryl and -adamantyl; said R 3 Unsubstituted or substituted by one or more of the following substituents: O, -OH, halogen, cyano, nitro, -CH(O), amino, -C 1~6 Alkyl, -C 2~6 Alkenyl, -C 2~6 Alkynyl, -OC 1~6 Alkyl, sulfonic acid, -C 1~6 Alkyl-halogen, -C 1~6 Alkyl-HS, -C 1~6 Alkyl-NH 3 + , -C 1~6 Alkyl-OH, -C 1~6 Alkyl-NH-C 1~6 Alkyl, -C 1~6 Alkyl-N(C 1~6 alkyl) 2 ;
[0046] (b) -6- to 14-membered aryl, -5- to 14-membered heterocyclic or -5- to 14-membered heteroaryl;
[0047] The 6- to 14-membered aryl, 5- to 14-membered heterocyclic or 5- to 14-membered heteroaryl is unsubstituted or substituted with one or more of the following substituents: O, -OH, halogen, cyano, nitro, -CH(O), amino, -C 1~6 Alkyl, -OC 1~6 Alkyl, -C 1~6 Alkyl-NH-C 1~6 Alkyl, -C 1~6 Alkyl-N(C 1~6 alkyl) 2 、-C(O)-OC1~6 Alkyl, -NH-C(O)-C 1~6 Alkyl, -SO 2 -C 1~6 Alkyl, -SO 2 -NH 2 、-SO 2 -NH-C 1~6 Alkyl, -SO 2 -N(C 1~6 alkyl) 2 , -6- to 14-membered aryl, -5- to 14-membered heterocyclic group, -5- to 14-membered heteroaryl;
[0048] (2) The N atom of the amide group -NH-CH(O) and the C atom are connected by -C 3~6 Alkylene-, -NH-C 2~6 Alkylene-, -NH-C(O)-C 1~6 Alkylene-, -C 1~6 Alkylene-NH-C(O)-, -NH-C 1~6 Alkylene-C(O)- or -C 1~6 Alkylene-C(O)- is connected to form a ring structure; the ring structure is optionally substituted by the following substituents: -C 1~6 Alkyl, -C 3~8 Cycloalkyl, -C 3~8 Cycloalkyl-C 1~6 Alkyl, -OC 1~6 alkyl, -6- to 14-membered aryl, -5- to 14-membered heterocyclic group, -5- to 14-membered heteroaryl, -C 1~6 Alkyl-6- to 14-membered aryl, -C 1~6 Alkyl-5- to 14-membered heterocyclic group, -C 1~6 alkyl-5- to 14-membered heteroaryl, trifluoroethyl; the 6- to 14-membered aryl, 5- to 14-membered heterocyclic group and 5- to 14-membered heteroaryl are optionally replaced by -OC 1~6 or, the cyclic structure is further combined with a 5- to 8-membered aryl group, a 5- to 8-membered heterocyclic group or a 5- to 8-membered heteroaryl group to form a condensed ring.
[0049] The heterocyclic group (including 5-14 members, 5-10 members, 5-8 members) contains 1-4 heteroatoms selected from N, S and O; the heteroaryl group (including 5-14 members, 5-10 members, 5-8 members) contains 1-4 heteroatoms selected from N, S and O.
[0050] R 2 Can be: -H, -halogen, -amino, -NO 2 , -CF 3 , -C 1~6 Alkyl, -C 1~6 Alkyl -OH, -OR4 、-C(O)-R 4 、-C(O)-NH 2 、-NH-C(O)-R 4 、-C(O)-OR 4 or -C(O)-ON(R 4 ) 2 ; R 4 Can be: H or C 1~6 alkyl.
[0051] The substituent of the amide group is connected to the N atom of the amino group and / or is the same as the C atom of the carbonyl group; and when there are two substituents, the two substituents may be the same or different.
[0052] The "halogen" refers to fluorine, chlorine, bromine or iodine as a substituent. When a halogen atom is used as a substituent, the number of substitutions is one or more, including 1, 2 or 3.
[0053] The "alkyl group" refers to a straight or branched chain alkyl group derived from an alkane by removing a hydrogen atom.
[0054] The "alkenyl group" refers to a straight chain, branched chain or cyclic alkenyl group containing a carbon-carbon double bond.
[0055] The "alkynyl group" refers to a straight chain, branched chain or cyclic alkynyl group containing a carbon-carbon triple bond.
[0056] The "cycloalkyl" is a fully hydrogenated non-aromatic ring consisting of a single, double or tricyclic ring. Thus, a cycloalkyl may be a single ring typically containing 3 to 7 ring atoms. Examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. At the same time, "cycloalkyl" also includes bridged bicycloalkyl systems.
[0057] The "alkyloxy group" refers to a group derived from an "alkyl" group connected to other moieties through -O-.
[0058] The "aryl" refers to a cyclic aromatic group whose ring atoms are carbon atoms, including monocyclic aromatic groups and condensed aromatic groups. Monocyclic aromatic groups refer to all unsaturated aromatic groups, and condensed aromatic groups refer to cyclic groups of aromatic rings formed by two or more cyclic structures sharing two adjacent carbon atoms, with at least one ring being all unsaturated.
[0059] The "heterocyclic group" refers to a saturated or unsaturated non-aromatic group containing 1, 2, 3 or 4 heteroatoms (N, O or S) and consisting of 1 to 3 rings.
[0060] The "heteroaryl" refers to an aromatic ring structure, including monocyclic heteroaryl and fused ring heteroaryl, wherein at least one of the ring atoms is a heteroatom (N, O or S) and the remaining ring atoms are independently selected from carbon, oxygen, nitrogen and sulfur.
[0061] Preferably, R 1 Can be:
[0062] (1) an amide group -NH-CH(O) substituted by one or more of the following substituents,
[0063] (a)-C 1~3 Alkyl-R 3 , -C 3~6 Cycloalkyl-R 3 , -C 2~5 Alkenyl-R 3 , -C 1~3 Alkyl-NH-R 3 , -C 1~3 Alkyl-OR 3 , or -OC 1~3 Alkyl-R 3 ; said R 3 Each is independently selected from: H, O, S, =NH, amino, halogen, cyano, -C 1~3 Alkyl, -C 3~6 Cycloalkyl, 6- to 14-membered aryl, 5- to 14-membered heterocyclic group, or 5- to 14-membered heteroaryl; the R 3 Unsubstituted or substituted by one or more of the following substituents: O, -OH, halogen, cyano, nitro, -CH(O), -S-OH, amino, -C 1~3 Alkyl, -C 2~5 Alkenyl, -C 2~5 Alkynyl, -OC 1~3 Alkyl, sulfonic acid, -C 1~3 Alkyl-halogen, -C 1~3 Alkyl-OH;
[0064] (b) -6- to 14-membered aryl, -5- to 14-membered heterocyclic group or -5- to 14-membered heteroaryl; the 6- to 14-membered aryl, 5- to 14-membered heterocyclic group or 5- to 14-membered heteroaryl group is unsubstituted or substituted by one or more of the following substituents: O, -OH, halogen, cyano, nitro, -CH(O), amino, -C 1~3 Alkyl, -OC 1~3 Alkyl, -C 1~3 Alkyl-NH-C 1~3 Alkyl, -C 1~3 Alkyl-N(C 1~3 alkyl) 2 、-C(O)-OC 1~3 Alkyl, -NH-C(O)-C 1~3 Alkyl, -SO 2 -C 1~3 Alkyl, -SO 2 -NH2 、-SO 2 -NH-C 1~3 Alkyl, -SO 2 -N(C 1~3 alkyl) 2 ;
[0065] (2) The N atom of the amide group -NH-CH(O) and the C atom are connected by -C 3~6 Alkylene-, -NH-C 2~4 Alkylene-, -NH-C(O)-C 1~3 Alkylene-, -C 1~3 Alkylene-NH-C(O)-, -NH-C 1~3 Alkylene-C(O)- or -C 1~3 Alkylene-C(O)- is connected to form a ring structure, and the ring structure is optionally substituted by the following substituents: -C 1~3 Alkyl, -C 3~6 Cycloalkyl, -C 3~6 Cycloalkyl-C 1~3 alkyl, -6- to 14-membered aryl, -5- to 14-membered heterocyclic group, -5- to 14-membered heteroaryl, -C 1~3 Alkyl-6- to 14-membered aryl, -C 1~3 Alkyl-5- to 14-membered heterocyclic group, -C 1~3 alkyl-5- to 14-membered heteroaryl, trifluoroethyl; the 6- to 14-membered aryl, 5- to 14-membered heterocyclic group, 5- to 14-membered heteroaryl are optionally replaced by -OC 1~3 Alkyl substitution;
[0066] The heterocyclic group contains 1 to 3 heteroatoms selected from N, S and O; the heteroaryl group contains 1 to 3 heteroatoms selected from N, S and O;
[0067] R 2 It can be: -H or halogen.
[0068] More preferably, R 1 Can be:
[0069] (1)-NH-C(O)-C 1~3 Alkyl-R 3 ; said R 3 is selected from: -6- to 10-membered aryl, -5- to 10-membered heterocyclic group, -5- to 10-membered heteroaryl; the R 3 Unsubstituted or substituted by one or more of the following substituents: O, -OH, halogen, cyano, nitro, -CH(O), -S-OH, amino, -C 1~3 Alkyl, -OC 1~3 Alkyl, sulfonic acid, -C 1~3 Alkyl-halogen, -C 1~3Alkyl-HS, -C 1~3 Alkyl-NH 3 + , -C 1~3 Alkyl-OH;
[0070] (2) -NH-C(O)-6- to 10-membered aryl, -NH-C(O)-5- to 10-membered heterocyclic group or -NH-C(O)-5- to 10-membered heteroaryl; the 6- to 10-membered aryl, 5- to 10-membered heterocyclic group or 5- to 10-membered heteroaryl group is unsubstituted or substituted with one or more of the following substituents: O, -OH, halogen, cyano, nitro, -CH(O), amino, -C 1~3 Alkyl, -OC 1~3 alkyl;
[0071] The heterocyclic group contains 1 to 3 heteroatoms selected from N, S and O; the heteroaryl group contains 1 to 3 heteroatoms selected from N, S and O;
[0072] R 2 Can be: -H.
[0073] More preferably, R 1 Specifically, it can be:
[0074]
[0075] In a specific embodiment, the diphenylpyrazole compound of general formula (I) or a pharmaceutically acceptable salt thereof is the following compound or a pharmaceutically acceptable salt thereof:
[0076]
[0077]
[0078]
[0079] Preferably, it is the following compound or a pharmaceutically acceptable salt thereof:
[0080]
[0081] This application is a follow-up application to Chinese patent application CN2021107606474 and PCT international application PCT / CN / 2021 / 105643. All contents of the aforementioned two applications are incorporated into this application by reference.
[0082] The present invention provides a diphenylpyrazole compound of general formula (I) or a pharmaceutically acceptable salt thereof, which can be used as a broad-spectrum anti-tuberculosis drug sensitizer / synergist for the treatment of tuberculosis (including non-drug-resistant tuberculosis and drug-resistant tuberculosis, especially drug-resistant tuberculosis). DETAILED DESCRIPTION
[0083] The present invention is described below by way of examples, but the present invention is not limited thereto. The experimental methods shown in the following examples are conventional methods unless otherwise specified. The reagents and materials shown are all commercially available products.
[0084] For the preparation of compounds PXG1, PXG2 and PXG22, please refer to Chinese patent application CN2021107606474. All the contents of the above two applications are incorporated into this application by reference.
[0085] Experimental Example 1 Inhibition experiment of compounds on non-drug-resistant strains of Mycobacterium tuberculosis and its resistant strains
[0086] Experiment: The non-drug-resistant strain of Mycobacterium tuberculosis H37rv and its drug-resistant strain IMCASHD1 were inoculated into a 250 mL Erlenmeyer flask containing 40 mL 7H9 medium (medium ingredients: 4.7 g 7H9 medium powder, 2 mL glycerol, 0.5 mL Tween80, 900 mL water and 100 mL filter-sterilized bacterial growth agent OADC), and cultured at 37°C (60 rpm) for 7 days until the mid-logarithmic growth period to obtain H37rv and IMCASHD1 bacterial suspensions. The H37rv and IMCASHD1 bacterial suspensions were diluted to a concentration of 1×10 5 CFU / mL, draw 100μL and add it to each well of a 96-well culture plate. Add 1μL of graded diluted compounds PXG1, PXG2 or PXG22 to each well. Seal each test plate with Parafilm sealing film and incubate in a 37°C constant temperature incubator for 7 days. After that, add 10μL of 10% resazurin to each well, continue to culture in a 37°C incubator for 3 days, and observe the color changes of each well. Use solvent DMSO as a negative control, rifampicin, isoniazid and ethambutol as positive controls, and make three parallel 96-well plates for each group. If there is bacterial growth in the wells of the 96-well plate, it will appear pink, and if there is no bacterial growth, it will appear blue. The final concentration of the compound corresponding to the blue well is the minimum inhibitory concentration MIC value of the compound for Mycobacterium tuberculosis.
[0087] Results: The experimental results are shown in Table 1. The MICs of compounds PXG1, PXG2 and PXG22 against H37rv and IMCASHD1 strains were all higher than 40 μg / mL. IMCASHD1 is a rifampicin-resistant Mycobacterium tuberculosis strain, and the MIC value of rifampicin against this resistant strain is 160 times that of H37rv strain. The MIC values of positive control drugs such as ethambutol and isoniazid against H37rv and IMCASHD1 strains changed less than 2 times, all below 5 μg / mL.
[0088] Table 1 MIC values of compounds PXG1, PXG2 and PXG22 against H37rv and IMCASHD1
[0089]
[0090] Conclusion: Compounds PXG1, PXG2 and PXG22 showed no antibacterial activity against drug-resistant and non-drug-resistant tuberculosis strains at a concentration of 40 μg / mL.
[0091] Experimental Example 2 Synergistic Effect Experiment of Compound PXG22 on Anti-tuberculosis Drugs
[0092] Experiment: The drug-resistant strain of Mycobacterium tuberculosis IMCASHD1 was inoculated into a 250mL Erlenmeyer flask containing 40mL 7H9 medium (medium ingredients: 4.7g 7H9 medium powder, 2mL glycerol, 0.5mL Tween80, 900mL water and 100mL filter-sterilized enrichment agent OADC), and the IMCASHD1 bacterial solution was obtained after 7 days of rotation culture at 37°C (speed of 60rpm). 100μL 7H9 medium was dispensed into each well of a 96-well culture plate. The combination method of the drug solution is as follows: The first drug, rifampicin, was arranged vertically from top to bottom on a 96-well plate according to the dilution concentration (the concentration of rifampicin in each horizontal row was the same), 1μL per well. The second drug was compound PXG22, which was arranged horizontally from left to right according to the dilution concentration (the concentration of the compound of the present invention in each vertical row was the same), 1μL per well. The concentrations of rifampicin and compound PXG22 in each well were recorded. At the same time, a group was added with 1 μL of gradient diluted compound PXG22 or rifampicin solution alone, and a blank control group without any drug was set up. The CFU was prepared to be 1×10 5 100 μL of bacterial solution was added to each well of a 96-well culture plate. After the 96-well culture plate was cultured in a 37°C incubator for 7 days, 10 μL of 10% resazurin was added. After further culture in a 37°C incubator for 3 days, the color change of each well was observed. Three parallel 96-well plates were made for each group. If there was bacterial growth in the wells of the 96-well plate, it would appear pink, and if there was no bacterial growth, it would appear blue. The final concentration of the compound corresponding to the blue well was recorded as the minimum inhibitory concentration (MIC) value of the compound against Mycobacterium tuberculosis.
[0093] The same method was used to determine the synergistic activity of compound PXG22 on ethambutol and isoniazid.
[0094] The fractional inhibitory concentration index (FICI) is used to determine whether the two drugs A and B have synergistic, antagonistic, unrelated or additive effects. The calculation formula of FICI is as follows:
[0095] FICI = MIC (group A combined) / MIC (group A alone) + MIC (group B combined) / MIC (group B alone)
[0096] The interpretation criteria of FICI are as follows: when FICI is less than 0.5, the two drugs have a synergistic effect; when FICI is between 0.5 and 1, the two drugs have an additive effect; when FICI is greater than 1 and less than 2, the two drugs have an unrelated effect; when FICI is greater than 2, the two drugs have an antagonistic effect.
[0097] The smaller the FICI, the better the synergy index, that is, the lower the concentration of the antimicrobial drug used.
[0098] Results: The experimental results are shown in Table 2. When 10 μg / mL of compound PXG22 was used in combination with 4 μg / mL rifampicin, 1 μg / mL ethambutol or 0.25 μg / mL isoniazid, the inhibition rate against drug-resistant strains of Mycobacterium tuberculosis (IMCASHD1) was 90%, and the FICI values were all less than 0.5, and the scores were ≤0.3, ≤0.45, and ≤0.375, respectively.
[0099] Table 2 Synergistic antibacterial activity of compound PXG22 against rifampicin, ethambutol and isoniazid
[0100]
[0101] Conclusion: Compound PXG22 has synergistic antibacterial activity against different types of anti-tuberculosis drugs such as rifampicin, ethambutol and isoniazid, and can significantly improve the inhibitory activity of anti-tuberculosis drugs against non-resistant and drug-resistant tuberculosis strains.
[0102] Experimental Example 3 Synergistic Effect of Compounds PXG1 and PXG2 on Rifampicin
[0103] Experiment: The drug-resistant strain of Mycobacterium tuberculosis IMCASHD1 was inoculated into a 250mL Erlenmeyer flask containing 40mL 7H9 medium (medium ingredients: 4.7g 7H9 medium powder, 2mL glycerol, 0.5mL Tween80, 900mL water and 100mL filter-sterilized enrichment agent OADC), and the IMCASHD1 bacterial solution was obtained after 7 days of rotation culture at 37°C (speed of 60rpm). 100μL 7H9 medium was dispensed into each well of a 96-well culture plate. The combination method of the drug solution is as follows: The first drug, rifampicin, was arranged vertically from top to bottom on the 96-well plate according to the dilution concentration (the concentration of rifampicin in each horizontal row was the same), 1μL per well. The second drug was compound PXG1 or PXG2, which was arranged horizontally from left to right according to the dilution concentration (the concentration of the compound in each vertical row was the same), 1μL per well. The concentrations of rifampicin and compound PXG1 or PXG2 in each well were recorded. At the same time, a group was added with 1 μL of gradient diluted compound PXG1 or PXG2 or rifampicin solution, and a blank control group without any drug was set up. 5 of bacterial solution, add 100 μL to each well of a 96-well culture plate. After the 96-well culture plate was placed in a 37°C incubator for 7 days, 10 μL of 10% resazurin was added, and after continuing to be cultured in a 37°C incubator for 3 days, the color change of each well was observed, and three parallel 96-well plates were made in each group. If there is bacterial growth in the wells of the 96-well plate, it will appear pink, and if there is no bacterial growth, it will appear blue. The final concentration of the compound corresponding to the blue well is the minimum inhibitory concentration MIC value of the compound for Mycobacterium tuberculosis. The FICI value was calculated with reference to the formula in Experimental Example 2, and the FICI value was used to determine whether compounds PXG1 and PXG2 have synergistic activity against rifampicin in inhibiting the growth of drug-resistant tuberculosis strain IMCASHD1.
[0104] Results: The experimental results are shown in Table 3. When 2.5 μg / mL of compounds PXG1 and PXG2 were used in combination with 4 μg / mL rifampicin, the FICI value was ≤0.1625 when the inhibition rate of the drug-resistant strain of Mycobacterium tuberculosis IMCASHD1 was 60%, and the FICI value was ≤0.35 when the inhibition rate of the drug-resistant strain of Mycobacterium tuberculosis (IMCASHD1) was 70%.
[0105] Table 3 Synergistic antibacterial activity of compounds PXG1 and PXG2 against rifampicin
[0106]
[0107] Conclusion: Compound PXG1 or PXG2 has synergistic antibacterial activity with rifampicin. The combination of the two can significantly enhance the inhibitory activity of rifampicin against non-resistant and resistant tuberculosis strains.
[0108] Experimental Example 4 Triple synergistic effect experiment of compounds PXG1 and PXG22 and anti-tuberculosis drugs
[0109] Experiment: The drug-resistant strain of Mycobacterium tuberculosis IMCASHD1 was inoculated into a 250mL triangular flask containing 40mL 7H9 medium (medium ingredients: 4.7g 7H9 medium powder, 2mL glycerol, 0.5mL Tween80, 900mL water and 100mL filtered sterilized enrichment agent OADC), and the IMCASHD1 bacterial solution was obtained after 7 days of rotary culture at 37°C (speed of 60rpm). 100μL 7H9 medium was dispensed into each well of a 96-well culture plate. The triple drug combination is as follows: PXG22+rifampicin+ethambutol, PXG22+rifampicin+isoniazid, PXG22+isoniazid+ethambutol, PXG1+rifampicin+ethambutol, PXG1+rifampicin+isoniazid, PXG1+isoniazid+ethambutol. The experimental steps and analysis methods are the same as those in Experimental Example 2. The FICI value was calculated with reference to the formula in Experimental Example 2, and the triple synergistic activity of compounds PXG1 and PXG22 and anti-tuberculosis drugs was evaluated by the FICI value.
[0110] Results: The experimental results are shown in Table 4. When 10 μg / mL of compound PXG22 was used in combination with "4 μg / mL rifampicin + 1 μg / mL ethambutol", "4 μg / mL rifampicin + 0.25 μg / mL isoniazid" and "1 μg / mL isoniazid + 1 μg / mL ethambutol", the inhibition rate of Mycobacterium tuberculosis resistant strain IMCASHD1 was greater than 90%, and its FICI values were <0.455, 0.35 and 0.455, respectively. 2.5 μ When the 5 μg / mL compound PXG1 was used in combination with "4 μg / mL rifampicin + 1 μg / mL ethambutol" and "4 μg / mL rifampicin + 0.25 μg / mL isoniazid", and the 5 μg / mL compound PXG1 was used in combination with "0.25 μg / mL isoniazid + 1 μg / mL ethambutol", the inhibition rate of the drug-resistant strain IMCASHD1 of Mycobacterium tuberculosis was greater than 90%, and the FICI values were 0.31, 0.315 and 0.048, respectively.
[0111] Table 4 Triple synergistic antibacterial activity of compounds PXG1 and PXG22 and anti-tuberculosis drugs
[0112]
[0113] Conclusion: Compound PXG1 or compound PXG22 has triple synergistic antibacterial activity with "rifampicin + ethambutol", "rifampicin + isoniazid" and "isoniazid + ethambutol", and can significantly improve the inhibitory activity of "rifampicin + ethambutol", "rifampicin + isoniazid" and "isoniazid + ethambutol" against non-resistant tuberculosis strains and drug-resistant tuberculosis strains.
[0114] Based on the above description of the invention, those skilled in the art can fully apply the present invention, and all the same principles or similar modifications should be deemed to be included in the scope of the present invention.
Claims
1. Use of a diphenylpyrazole compound of general formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating tuberculosis; in: R 1 for: (1) amide group -NH-CH(O) which is unsubstituted or substituted with one or more of the following substituents; (a)-C 1~6 Alkyl-R 3 , -C 3~8 Cycloalkyl-R 3 , -C 2~6 Alkenyl-R 3 , -C 2~6 Alkynyl-R 3 、-NH-R 3 、-N(R 3 )2. -C(O)-R 3 、-NH-C 1~6 Alkyl-R 3 , -C 1~6 Alkyl-NH-R 3 , -C 1~6 Alkyl-N(R 3 2. -C 1~6 Alkyl-OR 3 , -C 3~8 Cycloalkyl-OR 3 、-OC 1~6 Alkyl-R 3 , -C 1~6 Alkyl-OC 1~6 Alkyl-R 3 、-C(O)-NH-R 3 、-C(O)-N(R 3 )2. -NH-C(O)-R 3 , -C 1~6 Alkyl-NH-C(O)-R 3 , -C 1~6 Alkyl-NH-C(O)-OR 3 、-NH-C(O)-C 1~6 Alkyl-R 3 、-NH-C(O)-C 1~6 Alkyl-OR 3 、-C(O)-NH-C 1~6 Alkyl-R 3 or -C 1~6 Alkyl-SR 3 ; The R 3 Each is independently selected from: H, O, S, =NH, amino, halogen, cyano, -C 1~6 Alkyl, -C 3~8 Cycloalkyl, -SC 1~6 Alkyl, -S-OH, -SO2-C 1~6 alkyl, -6 to 14-membered aryl, -5 to 14-membered heterocyclic group, -5 to 14-membered heteroaryl and -adamantyl; said R 3 Unsubstituted or substituted by one or more of the following substituents: O, -OH, halogen, cyano, nitro, -CH(O), amino, -C 1~6 Alkyl, -C 2~6 Alkenyl, -C 2~6 Alkynyl, -OC 1~6 Alkyl, sulfonic acid, -C 1~6 Alkyl-halogen, -C 1~6 Alkyl-HS, -C 1~6 Alkyl-NH3 + , -C 1~6 Alkyl-OH, -C 1~6 Alkyl-NH-C 1~6 Alkyl, -C 1~6 Alkyl-N(C 1~6 Alkyl)2; (b) -6- to 14-membered aryl, -5- to 14-membered heterocyclic or -5- to 14-membered heteroaryl; The 6- to 14-membered aryl, 5- to 14-membered heterocyclic or 5- to 14-membered heteroaryl is unsubstituted or substituted with one or more of the following substituents: O, -OH, halogen, cyano, nitro, -CH(O), amino, -C 1~6 Alkyl, -OC 1~6 Alkyl, -C 1~6 Alkyl-NH-C 1~6 Alkyl, -C 1~6 Alkyl-N(C 1~6 Alkyl)2, -C(O)-OC 1~6 Alkyl, -NH-C(O)-C 1~6 Alkyl, -SO2-C 1~6 Alkyl, -SO2-NH2, -SO2-NH-C 1~6 Alkyl, -SO2-N(C 1~6 alkyl)2, -6- to 14-membered aryl, -5- to 14-membered heterocyclic group, -5- to 14-membered heteroaryl; (2) The N atom of the amide group -NH-CH(O) is bonded to the C atom via -C 3~6 Alkylene-, -NH-C 2~6 Alkylene-, -NH-C(O)-C 1~6 Alkylene-, -C 1~6 Alkylene-NH-C(O)-, -NH-C 1~6 Alkylene-C(O)- or -C 1~6 Alkylene-C(O)- is connected to form a ring structure; the ring structure is optionally substituted by the following substituents: -C 1~6 Alkyl, -C 3~8 Cycloalkyl, -C 3~8 Cycloalkyl-C 1~6 Alkyl, -OC 1~6 alkyl, -6- to 14-membered aryl, -5- to 14-membered heterocyclic group, -5- to 14-membered heteroaryl, -C 1~6 Alkyl-6- to 14-membered aryl, -C 1~6 Alkyl-5- to 14-membered heterocyclic group, -C 1~6 alkyl-5- to 14-membered heteroaryl, trifluoroethyl; the 6- to 14-membered aryl, 5- to 14-membered heterocyclic group and 5- to 14-membered heteroaryl are optionally replaced by -OC 1~6 Alkyl substitution; or, the cyclic structure is further combined with a 5- to 8-membered aryl group, a 5- to 8-membered heterocyclic group or a 5- to 8-membered heteroaryl group to form a condensed ring; The heterocyclic group contains 1 to 4 heteroatoms selected from N, S and O; the heteroaryl group contains 1 to 4 heteroatoms selected from N, S and O; R 2 For: -H, halogen, amino, -NO2, -CF3, -C 1~6 Alkyl, -C 1~6 Alkyl -OH, -OR 4 、-C(O)-R 4 、-C(O)-NH2、-NH-C(O)-R 4 、-C(O)-OR 4 or -C(O)-ON(R 4 )2; R 4 For: H or C 1~6 alkyl.
2. The use according to claim 1, which is the use of the diphenylpyrazole compound of general formula (I) or a pharmaceutically acceptable salt thereof in the preparation of an anti-tuberculosis drug sensitizer / synergist.
3. The use according to claim 1, which is the use of the diphenylpyrazole compound of general formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating non-drug-resistant tuberculosis and drug-resistant tuberculosis.
4. The use according to claim 2, wherein The anti-tuberculosis drug is a broad-spectrum anti-tuberculosis drug; Preferably, the anti-tuberculosis drug is selected from one or more of isoniazid, rifampicin, ethambutol, pyrazinamide, bedaquiline, delamanid and putamanid; More preferably, the anti-tuberculosis drug is selected from one or more of isoniazid, rifampicin and ethambutol.
5. The use according to any one of claims 1 to 4, wherein The drug comprises a diphenylpyrazole compound of general formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient; Preferably, the drug comprises a diphenylpyrazole compound of general formula (I) or a pharmaceutically acceptable salt thereof and an anti-tuberculosis drug, and a pharmaceutically acceptable excipient; More preferably, the weight ratio of the anti-tuberculosis drug to the diphenylpyrazole compound of general formula (I) or its pharmaceutically acceptable salt is 0.05-200:0.5-100, preferably 0.1-100:1-50, more preferably 0.1-50:3-30, more preferably 0.1-30:5-20, more preferably 0.25-16:
10.
6. The use according to claim 5, wherein Among the drugs: When the anti-tuberculosis drug is rifampicin and the diphenylpyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is compound PXG22, the weight ratio of rifampicin to compound PXG22 is 0.05-200:0.5-100, preferably 0.5-100:1-50, more preferably 1-30:2-30, more preferably 1-10:5-20, more preferably 4:10; or, When the anti-tuberculosis drug is ethambutol, and the diphenylpyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is compound PXG22, the weight ratio of ethambutol to compound PXG22 is 0.1-50:0.5-100, preferably 0.2-30:1-50, more preferably 0.5-20:2-30, more preferably 0.8-10:5-20, more preferably 1:10; or, When the anti-tuberculosis drug is isoniazid, the diphenylpyrazole compound of general formula (I) or a pharmaceutically acceptable salt thereof is compound PXG22, the weight ratio of ethambutol to compound PXG22 is 0.1-20:0.5-100, preferably 0.1-20:1-50, more preferably 0.1-10:2-30, more preferably 0.1-5:5-20, more preferably 0.25:10; or, When the anti-tuberculosis drug is rifampicin and the diphenylpyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is compound PXG1, the weight ratio of rifampicin to compound PXG1 is 0.5-100:0.25-100, preferably 0.5-50:0.3-50, more preferably 0.5-20:0.5-20, more preferably 1-10:1-5, more preferably 4:2.5; or, When the anti-tuberculosis drug is rifampicin, and the diphenylpyrazole compound of the general formula (I) or a pharmaceutically acceptable salt thereof is compound PXG2, the weight ratio of rifampicin to compound PXG2 is 0.5-100:0.25-100, preferably 0.5-50:0.3-50, more preferably 0.5-20:0.5-20, more preferably 1-10:1-5, more preferably 4:2.5; or, When the anti-tuberculosis drugs are rifampicin and ethambutol, and the diphenylpyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is compound PXG22, the weight ratio of rifampicin, ethambutol and compound PXG22 is 0.05-200:0.1-50:0.5-100, preferably 0.5-100:0.2-30:1-50, more preferably 1-30:0.5-20:2-30, more preferably 1-10:0.8-10:5-20, more preferably 4:1:10; or, When the anti-tuberculosis drugs are rifampicin and isoniazid, and the diphenylpyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is compound PXG22, the weight ratio of rifampicin, isoniazid and compound PXG22 is 0.05-200:0.1-20:0.5-100, preferably 0.5-100:0.1-20:1-50, more preferably 1-30:0.1-10:2-30, more preferably 1-10:0.1-5:5-20, more preferably 4:0.25:10; or, When the anti-tuberculosis drugs are isoniazid and ethambutol, and the diphenylpyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is compound PXG22, the weight ratio of isoniazid, ethambutol and compound PXG22 is 0.1-50:0.1-50:0.5-100, preferably 0.2-30:0.2-30:1-50, more preferably 0.5-20:0.5-20:2-30, more preferably 0.8-10:0.8-10:5-20, more preferably 1:1:10; or, When the anti-tuberculosis drugs are rifampicin and ethambutol, and the diphenylpyrazole compound of the general formula (I) or a pharmaceutically acceptable salt thereof is compound PXG1, the weight ratio of rifampicin, ethambutol and compound PXG1 is 0.5-100:0.1-50:0.25-100, preferably 0.5-50:0.2-30:0.3-50, more preferably 0.5-20:0.5-20:0.5-20, more preferably 1-10:0.8-10:1-5, more preferably 4:1:2.5; or, When the anti-tuberculosis drugs are rifampicin and isoniazid, and the diphenylpyrazole compound of the general formula (I) or a pharmaceutically acceptable salt thereof is compound PXG1, the weight ratio of rifampicin, isoniazid and compound PXG1 is 0.5-100:0.1-20:0.25-100, preferably 0.5-50:0.1-20:0.3-50, more preferably 0.5-20:0.1-10:0.5-20, more preferably 1-10:0.1-5:1-5, more preferably 4:0.25:2.5; or, When the anti-tuberculosis drugs are isoniazid and ethambutol, and the diphenylpyrazole compound of general formula (I) or its pharmaceutically acceptable salt is compound PXG1, the weight ratio of isoniazid, ethambutol and compound PXG1 is 0.1-20:0.1-50:0.5-100, preferably 0.1-20:0.2-30:0.5-50, more preferably 0.1-10:0.5-20:0.5-20, more preferably 0.1-5:0.8-10:1-10, more preferably 0.25:1:
5.
7. The use according to claim 1, wherein The tuberculosis strain is a non-drug-resistant strain of Mycobacterium tuberculosis H37rv or a drug-resistant strain of Mycobacterium tuberculosis IMCASHD1.
8. The use according to claim 1, wherein In the general formula (I), R 1 for: (1) an amide group -NH-CH(O) substituted by one or more of the following substituents, (a)-C 1~3 Alkyl-R 3 , -C 3~6 Cycloalkyl-R 3 , -C 2~5 Alkenyl-R 3 , -C 1~3 Alkyl-NH-R 3 , -C 1~3 Alkyl-OR 3 or -OC 1~3 Alkyl-R 3 ; said R 3 Each is independently selected from: H, O, S, =NH, amino, halogen, cyano, -C 1~3 Alkyl, -C 3~6 Cycloalkyl, -6 to 14-membered aryl, -5 to 14-membered heterocyclic group, -5 to 14-membered heteroaryl; the R 3 unsubstituted or substituted by one or more of the following substituents: O, -OH, halogen, cyano, nitro, -CH(O), -S-OH, amino, -C 1~3 Alkyl, -C 2~5 Alkenyl, -C 2~5 Alkynyl, -OC 1~3 Alkyl, sulfonic acid, -C 1~3 Alkyl-halogen, -C 1~3 Alkyl-OH; (b) -6- to 14-membered aryl, -5- to 14-membered heterocyclic group or -5- to 14-membered heteroaryl; the 6- to 14-membered aryl, 5- to 14-membered heterocyclic group or 5- to 14-membered heteroaryl group is unsubstituted or substituted by one or more of the following substituents: O, -OH, halogen, cyano, nitro, -CH(O), amino, -C 1~3 Alkyl, -OC 1~3 Alkyl, -C 1~3 Alkyl-NH-C 1~3 Alkyl, -C 1~3 Alkyl-N(C 1~3 Alkyl)2, -C(O)-OC 1~3 Alkyl, -NH-C(O)-C 1~3 Alkyl, -SO2-C 1~3 Alkyl, -SO2-NH2, -SO2-NH-C 1~3 Alkyl, -SO2-N(C 1~3 Alkyl)2; (2) The N atom of the amide group -NH-CH(O) is bonded to the C atom via -C 3~6 Alkylene-, -NH-C 2~4 Alkylene-, -NH-C(O)-C 1~3 Alkylene-, -C 1~3 Alkylene-NH-C(O)-, -NH-C 1~3 Alkylene-C(O)- or -C 1~3 Alkylene-C(O)- is connected to form a ring structure, and the ring structure is optionally substituted by the following substituents: -C 1~3 Alkyl, -C 3~6 Cycloalkyl, -C 3~6 Cycloalkyl-C 1~3 alkyl, -6- to 14-membered aryl, -5- to 14-membered heterocyclic group, -5- to 14-membered heteroaryl, -C 1~3 Alkyl-6- to 14-membered aryl, -C 1~3 Alkyl-5- to 14-membered heterocyclic group, -C 1~3 alkyl-5- to 14-membered heteroaryl, trifluoroethyl; the 6- to 14-membered aryl, 5- to 14-membered heterocyclic group and 5- to 14-membered heteroaryl are optionally replaced by -OC 1~3 Alkyl substitution; The heterocyclic group contains 1 to 3 heteroatoms selected from N, S and O; the heteroaryl group contains 1 to 3 heteroatoms selected from N, S and O; R 2 is: -H or halogen; Preferably, R 1 for: (1)-NH-C(O)-C 1~3 Alkyl-R 3 ; said R 3 is selected from: -6- to 10-membered aryl, -5- to 10-membered heterocyclic group, -5- to 10-membered heteroaryl; the R 3 unsubstituted or substituted by one or more of the following substituents: O, -OH, halogen, cyano, nitro, -CH(O), -S-OH, amino, -C 1~3 Alkyl, -OC 1~3 Alkyl, sulfonic acid, -C 1~3 Alkyl-halogen, -C 1~3 Alkyl-HS, -C 1~3 Alkyl-NH3 + , -C 1~3 Alkyl-OH; (2) -NH-C(O)-6- to 10-membered aryl, -NH-C(O)-5- to 10-membered heterocyclic group or -NH-C(O)-5- to 10-membered heteroaryl; the 6- to 10-membered aryl, 5- to 10-membered heterocyclic group or 5- to 10-membered heteroaryl group is unsubstituted or substituted with one or more of the following substituents: O, -OH, halogen, cyano, nitro, -CH(O), amino, -C 1~3 Alkyl, -OC 1~3 alkyl; The heterocyclic group contains 1 to 3 heteroatoms selected from N, S and O; the heteroaryl group contains 1 to 3 heteroatoms selected from N, S and O; R 2 For: -H; More preferably, R 1 for: More preferably, the diphenylpyrazole compound of general formula (I) or a pharmaceutically acceptable salt thereof is the following compound or a pharmaceutically acceptable salt thereof: More preferably, it is the following compound or a pharmaceutically acceptable salt thereof:
9. A drug for treating tuberculosis, comprising a diphenylpyrazole compound of general formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient; Preferably, it comprises a diphenylpyrazole compound of general formula (I) or a pharmaceutically acceptable salt thereof and an anti-tuberculosis drug, and a pharmaceutically acceptable excipient; More preferably, the weight ratio of the anti-tuberculosis drug to the diphenylpyrazole compound of general formula (I) or a pharmaceutically acceptable salt thereof is 0.05-200:0.5-100, preferably 0.1-100:1-50, more preferably 0.1-50:3-30, more preferably 0.1-30:5-20, most preferably 0.25-16:10; The anti-tuberculosis drug is a broad-spectrum anti-tuberculosis drug; Preferably, the anti-tuberculosis drug is selected from one or more of isoniazid, rifampicin, ethambutol, pyrazinamide, bedaquiline, delamanid and putamanid; More preferably, the anti-tuberculosis drug is selected from one or more of isoniazid, rifampicin and ethambutol.
10. The drug for treating tuberculosis according to claim 9, wherein: The anti-tuberculosis drugs are: rifampicin and ethambutol, rifampicin and isoniazid, isoniazid and ethambutol, or rifampicin, isoniazid and ethambutol.
